← ZhuZhou QianJin Pharmaceutical overview

ZhuZhou QianJin Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ZhuZhou QianJin Pharmaceutical Co Ltd (600479.CG)

Q3 202620 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

August 202620 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

Latest20 Jul – 26 Aug 2026

▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.